SCHEMBL30390254

SCHEMBL30390254

NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.50
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
PTGS2 P35354 1/20 0.46
THPO P40225 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ECE1 P42892 2/20 0.42
PTGS1 P23219 2/20 0.41
GSTK1 Q9Y2Q3 1/20 0.41
FOLH1 Q04609 1/20 0.40
SLC7A11 Q9UPY5 1/20 0.39
MME P08473 2/20 0.38
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10308197 1.00 ACE (0.50) ACEKDM4EMAPTTHRBALOX15
SCHEMBL16770226 1.00 ACE (0.50) ACEKDM4EMAPTTHRBALOX15
SCHEMBL23091324 0.97 ACE (0.53) ACEKDM4EMAPTTHRBALOX15
SCHEMBL27900740 0.97 ACE (0.53) ACEKDM4EMAPTTHRBALOX15
SCHEMBL14957276 0.97 ACE (0.53) ACEKDM4EMAPTTHRBALOX15
SCHEMBL30288037 0.95 ACE (0.49) ACEKDM4EMAPTTHRBALOX15
SCHEMBL30287995 0.95 ACE (0.49) ACEKDM4EMAPTTHRBALOX15
SCHEMBL6810737 0.95 ECE1 (0.48) ACEKDM4EMAPTTHRBALOX15
SCHEMBL6810742 0.95 ECE1 (0.48) ACEKDM4EMAPTTHRBALOX15
SCHEMBL6809859 0.94 ECE1 (0.47) ACEKDM4EMAPTTHRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748447-A2 INFLUENZA VIRUS VACCINES AND USES THEREOF Icahn School of Medicine at Mount Sinai (US) 2026-05-27 EP disclosed
EP-4241785-B1 INFLUENZA VIRUS VACCINES AND USES THEREOF ICAHN SCHOOL MED MOUNT SINAI (US) 2026-01-28 EP disclosed
US-20260001918-A1 INFLUENZA VIRUS VACCINES AND USES THEREOF ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2026-01-01 US disclosed
EP-4241785-A2 INFLUENZA VIRUS VACCINES AND USES THEREOF Icahn School of Medicine at Mount Sinai (US) 2023-09-13 EP disclosed
EP-2758075-B1 INFLUENZA VIRUS VACCINES AND USES THEREOF ICAHN SCHOOL MED MOUNT SINAI (US) 2023-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001918-A1 INFLUENZA VIRUS VACCINES AND USES THEREOF CD44, SIGLEC7, SIGLEC9 ACE 2757/4885KDM4E 2871/4885MAPT 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.